K. Racz, A. Keller and A. Lysgaard have no conflicts of interest to declare. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and selleck chemicals llc reproduction in any

medium, provided the original author(s) and source are credited. References 1. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M (1992) Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 74:118–123PubMedCrossRef 2. Boot AM, van der Sluis IM, Krenning EP, de Muinck Keizer-Schrama SM (2009) Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency. Horm Res 71:364–371PubMedCrossRef www.selleckchem.com/products/GDC-0449.html 3. de Boer H, Blok GJ, van Lingen A, Teule GJ, Lips P, Regorafenib cost van der Veen EA (1994) Consequences of

childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 9:1319–1326PubMedCrossRef 4. Holmer H, Svensson J, Rylander L, Johannsson G, Rosen T, Bengtsson BA, Thoren M, Hoybye C, Degerblad M, Bramnert M, Hagg E, Engstrom BE, Ekman B, Thorngren KG, Hagmar L, Erfurth EM (2007) Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J Bone Miner Res 22:1842–1850PubMedCrossRef 5. Bouillon R, Koledova E, Bezlepkina O, Nijs J, Shavrikhova E, Nagaeva E,

Chikulaeva O, Peterkova V, Dedov I, Bakulin A, Oganov V, Attanasio AF (2004) Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 89:4993–4998PubMedCrossRef 6. Baroncelli GI, Bertelloni S, Sodini F, Saggese G (2002) Lumbar bone mineral density at final height and prevalence of fractures in treated children with GH deficiency. J Clin Endocrinol Metab 87:3624–3631PubMedCrossRef 7. Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R (1991) Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 73:555–563PubMedCrossRef 8. Mauras N (2010) GH use in the transition pentoxifylline of adolescence to adulthood. Endocr Dev 18:109–125PubMedCrossRef 9. Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A (2000) Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 85:970–976PubMedCrossRef 10. Underwood LE, Attie KM, Baptista J (2003) Growth hormone (GH) dose–response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 88:5273–5280PubMedCrossRef 11.